161 related articles for article (PubMed ID: 29206780)
1. Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?
Basu S; Parghane RV; Ostwal V; Shrikhande SV
Nucl Med Commun; 2018 Jan; 39(1):94-95. PubMed ID: 29206780
[No Abstract] [Full Text] [Related]
2. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.
Kaemmerer D; Prasad V; Daffner W; Hörsch D; Klöppel G; Hommann M; Baum RP
World J Gastroenterol; 2009 Dec; 15(46):5867-70. PubMed ID: 19998512
[TBL] [Abstract][Full Text] [Related]
3. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
[TBL] [Abstract][Full Text] [Related]
4. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
Kwekkeboom DJ; Krenning EP
Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
[TBL] [Abstract][Full Text] [Related]
5. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
[TBL] [Abstract][Full Text] [Related]
6. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic neuroendocrine tumors.
Muniraj T; Vignesh S; Shetty S; Thiruvengadam S; Aslanian HR
Dis Mon; 2013 Jan; 59(1):5-19. PubMed ID: 23312533
[No Abstract] [Full Text] [Related]
8. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
9. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714
[TBL] [Abstract][Full Text] [Related]
10. Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.
Soeiro P; Martins H; Silva R; Moreira AP
BMJ Case Rep; 2020 Mar; 13(3):. PubMed ID: 32234855
[No Abstract] [Full Text] [Related]
11. Joint guidance on peptide receptor radionuclide therapy in neuroendocrine tumors.
Delbeke D; Graham MM
J Nucl Med; 2013 May; 54(5):663. PubMed ID: 23536220
[No Abstract] [Full Text] [Related]
12. Addendum to the editorial "Joint guidance on peptide receptor radionuclide therapy in neuroendocrine tumors".
Delbeke D; Graham MM
J Nucl Med; 2013 Jul; 54(7):1170. PubMed ID: 23733924
[No Abstract] [Full Text] [Related]
13. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
Kalshetty A; Ramaswamy A; Ostwal V; Basu S
Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):53-4. PubMed ID: 26562579
[TBL] [Abstract][Full Text] [Related]
15. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
Lo Russo G; Pusceddu S; Prinzi N; Imbimbo M; Proto C; Signorelli D; Vitali M; Ganzinelli M; Maccauro M; Buzzoni R; Seregni E; de Braud F; Garassino MC
Tumour Biol; 2016 Oct; 37(10):12991-13003. PubMed ID: 27460087
[TBL] [Abstract][Full Text] [Related]
16. Emerging treatment modalities for advanced pancreatic neuroendocrine tumors.
Sindoni A; Famà F; Gioffre-Florio M; Baldari S
Hormones (Athens); 2016 Oct; 15(4):563-564. PubMed ID: 28222417
[No Abstract] [Full Text] [Related]
17. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
18. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.
Barber TW; Hofman MS; Thomson BN; Hicks RJ
Eur J Surg Oncol; 2012 Jan; 38(1):64-71. PubMed ID: 21906907
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant downsizing by internal radiation: a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors.
Ezziddin S; Lauschke H; Schaefers M; Meyer C; van Essen M; Biersack HJ; Kwekkeboom DJ; Ahmadzadehfar H
Clin Nucl Med; 2012 Jan; 37(1):102-4. PubMed ID: 22157044
[No Abstract] [Full Text] [Related]
20. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?
Perysinakis I; Aggeli C; Kaltsas G; Zografos GN
Hormones (Athens); 2016; 15(1):15-22. PubMed ID: 26732156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
